Sera Selina Weyer-Fahlbusch
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sera Selina Weyer-Fahlbusch has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
- Laura Susok
Department of Dermatology, Dortmund Hospital gGmbH, University Witten/Herdecke, 44137 Dortmund, Germany
5 shared publications - Nessr Abu Rached
Department of Dermatology, Bielefeld University, Medical School and University Medical Center East Westphalia-Lippe (OWL), Klinikum Bielefeld Rosenhöhe
5 shared publications - Thilo Gambichler
Department of Dermatology Ruhr‐University Bochum Bochum Germany
5 shared publications - Stefanie Boms
Department of Dermatology, Christian Hospital Unna, 59423 Unna, Germany
3 shared publications - Alexander Kreuter
Klinik für Dermatologie Venerologie und Allergologie Helios St. Elisabeth Klinik Oberhausen Universität Witten/Herdecke Oberhausen Deutschland
2 shared publications - Julia Hyun
Department of Dermatology, Venereology, and Allergology, Helios St. Johannes Hospital Duisburg, University of Witten/Herdecke, Duisburg, Germany
2 shared publications
Latest Publications
- Open Access
- 28 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 100
General health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy
Purpose: Overall survival (OS) of Merkel cell carcinoma (MCC) patients is strongly influenced by health. Sentinel lymph node biopsy (SLNB) is recommended for staging. We evaluated whether SLNB is associated with OS in clinically node-negative MCC and contrasted tumor factors with patient frailty. Methods: STROBE-compliant cohort across eight centers in Germany (2004–2024). We included 271 primary stage I–II MCC; 167 underwent SLNB and 104 did not. The primary outcome was OS; disease-specific survival (DSS) and progression-free probability (PFP) were secondary. Kaplan–Meier and Cox models were used. Confounding by indication was addressed with 1:1 propensity score matching and sensitivity analyses. Results: Patients receiving SLNB were younger (median 74 vs 82 years; p < 0.001) and less comorbid (Charlson 4 vs 5). Ten-year OS was 69.5% with SLNB versus 45.2% without (log-rank p < 0.0001); unadjusted HR 0.34 (95% CI 0.20–0.59). In the matched cohort, SLNB remained associated with lower all-cause mortality (HR 0.56, 95% CI 0.34–0.93; p = 0.024). DSS did not differ (HR 1.09, 95% CI 0.55–2.13; p = 0.81). For PFP, unadjusted curves favored SLNB ( p =0.0045), but the matched analysis was not significant (HR 0.53, 95% CI 0.23–1.26). Sensitivity analyses suggested benefit: overlap weighting HR 0.49 (95% CI 0.33–0.73; p = 0.00045) and a stage-restricted match HR 0.36 (95% CI 0.13–0.99; p = 0.048). Conclusions: SLNB was associated with improved OS after adjustment, supporting its role in staging and risk stratification. The absence of DSS and matched PFP differences highlights the influence of overall health; residual confounding by indication cannot be excluded.
- 28 April 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (4) , 100
Open AccessGeneral health versus tumor stage: determinants of survival in Merkel cell carcinoma assessed by sentinel lymph node biopsy
Purpose: Overall survival (OS) of Merkel cell carcinoma (MCC) patients is strongly influenced by health. Sentinel lymph node biopsy (SLNB) is recommended for staging. We evaluated whether SLNB is associated with OS in clinically node-negative MCC and contrasted tumor factors with patient frailty. Methods: STROBE-compliant cohort across eight centers in Germany (2004–2024). We included 271 primary stage I–II MCC; 167 underwent SLNB and 104 did not. The primary outcome was OS; disease-specific survival (DSS) and progression-free probability (PFP) were secondary. Kaplan–Meier and Cox models were used. Confounding by indication was addressed with 1:1 propensity score matching and sensitivity analyses. Results: Patients receiving SLNB were younger (median 74 vs 82 years; p < 0.001) and less comorbid (Charlson 4 vs 5). Ten-year OS was 69.5% with SLNB versus 45.2% without (log-rank p < 0.0001); unadjusted HR 0.34 (95% CI 0.20–0.59). In the matched cohort, SLNB remained associated with lower all-cause mortality (HR 0.56, 95% CI 0.34–0.93; p = 0.024). DSS did not differ (HR 1.09, 95% CI 0.55–2.13; p = 0.81). For PFP, unadjusted curves favored SLNB ( p =0.0045), but the matched analysis was not significant (HR 0.53, 95% CI 0.23–1.26). Sensitivity analyses suggested benefit: overlap weighting HR 0.49 (95% CI 0.33–0.73; p = 0.00045) and a stage-restricted match HR 0.36 (95% CI 0.13–0.99; p = 0.048). Conclusions: SLNB was associated with improved OS after adjustment, supporting its role in staging and risk stratification. The absence of DSS and matched PFP differences highlights the influence of overall health; residual confounding by indication cannot be excluded.
- Open Access
- 25 February 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (2) , 50
Predictors of response and survival in cemiplimab–treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany
Purpose: To assess the association of systemic immune-inflammation biomarkers (SIIBs) and other clinical parameters with objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and immune-related adverse events (irAEs) in patients with advanced cSCC treated with cemiplimab, and to compare baseline SIIBs levels between early-stage and advanced-stage disease. Methods: A retrospective multicenter cohort of 110 immunocompetent advanced cSCC patients treated with cemiplimab was analysed. ORR was assessed using logistic regression; PFS and OS were evaluated using Cox models, and DSS using cause-specific hazards. ROC analyses assessed biomarker discrimination. Baseline SIIBs (LMR, NLR, SIRI) were compared between early-stage (AJCC I/II, non-ICI cohort, n = 59) and advanced-stage disease. Tumor characteristics, body mass index (BMI), and Charlson comorbidity index were evaluated. Results: Among 110 patients, 79 (71.8%) achieved an objective response. Baseline LMR showed modest discrimination for ORR (AUC 0.64, 95% CI 0.53–0.75; p = 0.015) but did not retain statistical significance after adjustment for baseline clinical covariates (OR 1.35, 95% CI 0.95–1.91; p = 0.096). Higher BMI was associated with improved PFS (HR 0.94 per kg/m 2 , 95% CI 0.89–1.00; p = 0.035) and showed a borderline association with OS (HR 0.92 per kg/m 2 , 95% CI 0.85–1.00; p = 0.051). AJCC stage IV strongly predicted DSS (HR 14.03, 95% CI 1.80–109.67; p = 0.012). Baseline LMR was higher in early-stage than in advanced-stage disease (Hodges-Lehmann difference 0.43; p = 0.011), whereas NLR did not differ significantly between stage groups; SIRI was modestly higher in advanced-stage disease ( p = 0.029). Conclusions: In immunocompetent patients with advanced cSCC receiving PD-1 inhibition, BMI was prognostic for survival and AJCC stage remained the key driver of cSCC-specific mortality. Baseline LMR showed a modest association with response and differed between early- and advanced-stage disease, whereas other SIIBs were not consistently linked to tumor progression. Prospective validation is warranted.
- 25 February 2026
- Published by Springer Nature in Journal of Cancer Research and Clinical Oncology
- Vol. 152 (2) , 50
Open AccessPredictors of response and survival in cemiplimab–treated cutaneous squamous cell carcinoma: multicenter real-world evidence from Germany
Purpose: To assess the association of systemic immune-inflammation biomarkers (SIIBs) and other clinical parameters with objective response rate (ORR), progression-free survival (PFS), overall survival (OS), disease-specific survival (DSS), and immune-related adverse events (irAEs) in patients with advanced cSCC treated with cemiplimab, and to compare baseline SIIBs levels between early-stage and advanced-stage disease. Methods: A retrospective multicenter cohort of 110 immunocompetent advanced cSCC patients treated with cemiplimab was analysed. ORR was assessed using logistic regression; PFS and OS were evaluated using Cox models, and DSS using cause-specific hazards. ROC analyses assessed biomarker discrimination. Baseline SIIBs (LMR, NLR, SIRI) were compared between early-stage (AJCC I/II, non-ICI cohort, n = 59) and advanced-stage disease. Tumor characteristics, body mass index (BMI), and Charlson comorbidity index were evaluated. Results: Among 110 patients, 79 (71.8%) achieved an objective response. Baseline LMR showed modest discrimination for ORR (AUC 0.64, 95% CI 0.53–0.75; p = 0.015) but did not retain statistical significance after adjustment for baseline clinical covariates (OR 1.35, 95% CI 0.95–1.91; p = 0.096). Higher BMI was associated with improved PFS (HR 0.94 per kg/m 2 , 95% CI 0.89–1.00; p = 0.035) and showed a borderline association with OS (HR 0.92 per kg/m 2 , 95% CI 0.85–1.00; p = 0.051). AJCC stage IV strongly predicted DSS (HR 14.03, 95% CI 1.80–109.67; p = 0.012). Baseline LMR was higher in early-stage than in advanced-stage disease (Hodges-Lehmann difference 0.43; p = 0.011), whereas NLR did not differ significantly between stage groups; SIRI was modestly higher in advanced-stage disease ( p = 0.029). Conclusions: In immunocompetent patients with advanced cSCC receiving PD-1 inhibition, BMI was prognostic for survival and AJCC stage remained the key driver of cSCC-specific mortality. Baseline LMR showed a modest association with response and differed between early- and advanced-stage disease, whereas other SIIBs were not consistently linked to tumor progression. Prospective validation is warranted.
- Open Access
Melanoma Presentations Before, During, and After the COVID-19 Pandemic: A Multicenter Cohort Study from North Rhine-Westphalia, Germany
Background: The COVID-19 pandemic disrupted access to routine dermatologic care and may have delayed melanoma diagnosis and management. Evidence on the post-pandemic period and on hospital-based referral cohorts remains limited. We assessed melanoma presentations before, during and after the pandemic in three skin cancer centers in North Rhine-Westphalia, Germany. Methods: We conducted a multicenter retrospective cohort study of inpatients with cutaneous melanoma grouped into Phase 1 (February 2017–February 2020), Phase 2 (March 2020–March 2023), and Phase 3 (April 2023–May 2024). The primary endpoint was Breslow tumor thickness (TT) among invasive melanomas, analyzed using multivariable log-linear regression adjusted for center, age, sex, anatomic site, and histologic subtype. Secondary endpoints included T category and AJCC stage distributions (including stage 0/Tis), macroscopic primary tumor specimen dimensions (area and volume; available cases), staging work-up and sentinel lymph node biopsy (SLNB) indicators, and exploratory laboratory parameters (LDH, S100, CRP) and dermal mitotic rate. Results: We included 2960 patients (Phase 1: 1162; Phase 2: 1251; Phase 3: 547). Median TT among invasive melanomas was 1.1 mm (IQR 0.6–2.3), 1.1 mm (0.5–2.4), and 1.0 mm (0.5–2.3) across phases (p = 0.037). In adjusted models among invasive tumors, TT did not increase (Phase 2 vs. Phase 1: 0.97, 95% CI 0.90–1.04; Phase 3 vs. Phase 1: 0.94, 0.86–1.03). AJCC stage 0 decreased from 7.7% and 6.1% to 2.0%; adjusted OR Phase 3 vs. Phase 1: 0.24 (95% CI 0.13–0.46). Within invasive tumors, the distribution of T categories (T1a–T4) and AJCC stages I–IV was similar across periods. Among cases with available macroscopic primary tumor specimen dimensions, median area and volume were higher during and after the pandemic (area p = 0.030; volume p = 0.042), but period effects attenuated in models adjusted for TT. Exploratory analyses suggested a higher proportion of elevated LDH and a lower proportion of elevated S100 across periods, while CRP and dermal mitotic rate showed no clear period shift. Conclusions: In this large melanoma inpatient cohort, the pandemic period was not associated with thicker invasive melanomas after covariate adjustment. However, a persistent reduction in stage 0/Tis presentations in the post-pandemic period suggests ongoing disruption or shifting of early detection and referral pathways. Exploratory increases in macroscopic tumor dimensions may point to changes not captured by thickness alone, but require cautious interpretation given missingness and potential documentation effects.
Open AccessMelanoma Presentations Before, During, and After the COVID-19 Pandemic: A Multicenter Cohort Study from North Rhine-Westphalia, Germany
Background: The COVID-19 pandemic disrupted access to routine dermatologic care and may have delayed melanoma diagnosis and management. Evidence on the post-pandemic period and on hospital-based referral cohorts remains limited. We assessed melanoma presentations before, during and after the pandemic in three skin cancer centers in North Rhine-Westphalia, Germany. Methods: We conducted a multicenter retrospective cohort study of inpatients with cutaneous melanoma grouped into Phase 1 (February 2017–February 2020), Phase 2 (March 2020–March 2023), and Phase 3 (April 2023–May 2024). The primary endpoint was Breslow tumor thickness (TT) among invasive melanomas, analyzed using multivariable log-linear regression adjusted for center, age, sex, anatomic site, and histologic subtype. Secondary endpoints included T category and AJCC stage distributions (including stage 0/Tis), macroscopic primary tumor specimen dimensions (area and volume; available cases), staging work-up and sentinel lymph node biopsy (SLNB) indicators, and exploratory laboratory parameters (LDH, S100, CRP) and dermal mitotic rate. Results: We included 2960 patients (Phase 1: 1162; Phase 2: 1251; Phase 3: 547). Median TT among invasive melanomas was 1.1 mm (IQR 0.6–2.3), 1.1 mm (0.5–2.4), and 1.0 mm (0.5–2.3) across phases (p = 0.037). In adjusted models among invasive tumors, TT did not increase (Phase 2 vs. Phase 1: 0.97, 95% CI 0.90–1.04; Phase 3 vs. Phase 1: 0.94, 0.86–1.03). AJCC stage 0 decreased from 7.7% and 6.1% to 2.0%; adjusted OR Phase 3 vs. Phase 1: 0.24 (95% CI 0.13–0.46). Within invasive tumors, the distribution of T categories (T1a–T4) and AJCC stages I–IV was similar across periods. Among cases with available macroscopic primary tumor specimen dimensions, median area and volume were higher during and after the pandemic (area p = 0.030; volume p = 0.042), but period effects attenuated in models adjusted for TT. Exploratory analyses suggested a higher proportion of elevated LDH and a lower proportion of elevated S100 across periods, while CRP and dermal mitotic rate showed no clear period shift. Conclusions: In this large melanoma inpatient cohort, the pandemic period was not associated with thicker invasive melanomas after covariate adjustment. However, a persistent reduction in stage 0/Tis presentations in the post-pandemic period suggests ongoing disruption or shifting of early detection and referral pathways. Exploratory increases in macroscopic tumor dimensions may point to changes not captured by thickness alone, but require cautious interpretation given missingness and potential documentation effects.
- 15 October 2025
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 51 (10) , 332
Invers auftretende asymptomatische, scharf abgegrenzte, graubraune Plaques
Eine 24-jährige Patientin wird vorgestellt wegen seit 6 Monaten zunehmenden scharf abgegrenzten, graubraunen Plaques, die zuerst submammär und später inguinal in Erscheinung getreten sind ([ Abb. 1 a ]). Subjektive Symptome wie Juckreiz bestehen nicht. Außer einer Insulinresistenz und Adipositas sind bei der Patientin keine weiteren Pathologien bekannt. Unter der klinischen Verdachtsdiagnose eines Lichen planus pigmentosus inversus (LIPPI) erfolgt eine histopathologische Untersuchung, die das Bild einer Interface-Dermatitis mit ausgeprägter Pigmentinkontinenz zeigt, ohne dass dabei eine ausgeprägte Akanthose oder Hypergranulose erkennbar sind ([ Abb. 1 b ]). Der seltene LIPPI wie auch der häufiger auftretende Lichen planus pigmentosus/actinicus (LPP) stellen Varianten des klassischen Lichen planus dar, der oft auch mit mukosaler Beteiligung einhergeht. Dennoch sind klinisch der LIPPI (inverse, intertriginöse Regionen) und LPP (sonnenexponierte Regionen) gut durch ihre Prädilektionsstellen zu unterscheiden. Dementsprechend scheinen sich auch die pathophysiologischen Mechanismen zu unterscheiden, wobei beim LIPPI eher mechanische Irritation/Friktion diskutiert werden und beim LPP ultraviolette Strahlung als Auslöser angesehen wird. Anders als der klassische Lichen planus ist der LIPPI schwerer behandelbar und zeigt eher einen längeren Verlauf [1]. Article published online: 15 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- 15 October 2025
- Published by Georg Thieme Verlag KG in Aktuelle Dermatologie
- Vol. 51 (10) , 332
Invers auftretende asymptomatische, scharf abgegrenzte, graubraune Plaques
Eine 24-jährige Patientin wird vorgestellt wegen seit 6 Monaten zunehmenden scharf abgegrenzten, graubraunen Plaques, die zuerst submammär und später inguinal in Erscheinung getreten sind ([ Abb. 1 a ]). Subjektive Symptome wie Juckreiz bestehen nicht. Außer einer Insulinresistenz und Adipositas sind bei der Patientin keine weiteren Pathologien bekannt. Unter der klinischen Verdachtsdiagnose eines Lichen planus pigmentosus inversus (LIPPI) erfolgt eine histopathologische Untersuchung, die das Bild einer Interface-Dermatitis mit ausgeprägter Pigmentinkontinenz zeigt, ohne dass dabei eine ausgeprägte Akanthose oder Hypergranulose erkennbar sind ([ Abb. 1 b ]). Der seltene LIPPI wie auch der häufiger auftretende Lichen planus pigmentosus/actinicus (LPP) stellen Varianten des klassischen Lichen planus dar, der oft auch mit mukosaler Beteiligung einhergeht. Dennoch sind klinisch der LIPPI (inverse, intertriginöse Regionen) und LPP (sonnenexponierte Regionen) gut durch ihre Prädilektionsstellen zu unterscheiden. Dementsprechend scheinen sich auch die pathophysiologischen Mechanismen zu unterscheiden, wobei beim LIPPI eher mechanische Irritation/Friktion diskutiert werden und beim LPP ultraviolette Strahlung als Auslöser angesehen wird. Anders als der klassische Lichen planus ist der LIPPI schwerer behandelbar und zeigt eher einen längeren Verlauf [1]. Article published online: 15 October 2025 © 2025. Thieme. All rights reserved. Georg Thieme Verlag KG Oswald-Hesse-Straße 50, 70469 Stuttgart, Germany
- Open Access
Overall Survival of Patients with Melanoma of Unknown Primary Versus Melanoma of Known Primary Under Immunotherapy and Targeted Therapy: A Systematic Review and Meta-Analysis
Background: Melanoma of unknown primary (MUP) is a rare and distinct clinical subtype of metastatic melanoma, in which no identifiable primary tumor is found. The prognosis of MUP compared to melanoma with known primary (MKP) remains unclear, especially in the era of novel therapies like immune checkpoint inhibitors (ICIs) and targeted therapies. This meta-analysis aims to compare the overall survival (OS) of MUP and MKP patients under these therapies. Methods: This systematic review was conducted in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). A systematic search of major databases was conducted, yielding six eligible studies (nine study arms) that assessed the survival outcomes of MUP and MKP patients treated with immunotherapies and targeted therapies. We pooled the hazard ratios (HRs) for OS using both fixed and random effects models. Heterogeneity was assessed with the I2 statistic followed by a Baujat plot, and publication bias was evaluated using funnel plots and Egger’s test. Results: Our analysis revealed a borderline significant HR of 0.90 (95% CI: [0.81, 1.00], p = 0.04) under the fixed effect model, suggesting a potential survival benefit for MUP patients. However, the random effects model, accounting for study heterogeneity, showed no significant difference in OS between MUP and MKP (HR = 0.87, 95% CI: [0.73, 1.05], p = 0.15). Significant heterogeneity (I2 = 66.9%, p = 0.0022) was observed across studies. No substantial publication bias was detected. Conclusion: While the trend observed in the fixed effect model suggests a potential benefit for MUP patients, the random effects analysis indicates no significant difference between MUP and MKP in terms of OS. These findings underscore the importance of accounting for study heterogeneity and highlight the need for further prospective studies to better understand the impact of novel therapies on MUP.
Open AccessOverall Survival of Patients with Melanoma of Unknown Primary Versus Melanoma of Known Primary Under Immunotherapy and Targeted Therapy: A Systematic Review and Meta-Analysis
Background: Melanoma of unknown primary (MUP) is a rare and distinct clinical subtype of metastatic melanoma, in which no identifiable primary tumor is found. The prognosis of MUP compared to melanoma with known primary (MKP) remains unclear, especially in the era of novel therapies like immune checkpoint inhibitors (ICIs) and targeted therapies. This meta-analysis aims to compare the overall survival (OS) of MUP and MKP patients under these therapies. Methods: This systematic review was conducted in line with the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA). A systematic search of major databases was conducted, yielding six eligible studies (nine study arms) that assessed the survival outcomes of MUP and MKP patients treated with immunotherapies and targeted therapies. We pooled the hazard ratios (HRs) for OS using both fixed and random effects models. Heterogeneity was assessed with the I2 statistic followed by a Baujat plot, and publication bias was evaluated using funnel plots and Egger’s test. Results: Our analysis revealed a borderline significant HR of 0.90 (95% CI: [0.81, 1.00], p = 0.04) under the fixed effect model, suggesting a potential survival benefit for MUP patients. However, the random effects model, accounting for study heterogeneity, showed no significant difference in OS between MUP and MKP (HR = 0.87, 95% CI: [0.73, 1.05], p = 0.15). Significant heterogeneity (I2 = 66.9%, p = 0.0022) was observed across studies. No substantial publication bias was detected. Conclusion: While the trend observed in the fixed effect model suggests a potential benefit for MUP patients, the random effects analysis indicates no significant difference between MUP and MKP in terms of OS. These findings underscore the importance of accounting for study heterogeneity and highlight the need for further prospective studies to better understand the impact of novel therapies on MUP.
- Open Access
Impaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis
Background: The gut microbiome plays a pivotal role in shaping systemic immunity and modulating anti-tumor responses. Preclinical and clinical studies have shown that higher gut microbial diversity and the presence of specific commensal taxa correlate with improved responses to immune checkpoint inhibitors (ICI) in melanoma. Conversely, broad-spectrum antibiotics can induce dysbiosis, reducing T cell activation and cytokine production, and have been linked to diminished ICI efficacy in several cancer types. Methods: We conducted a systematic review and meta-analysis of seven retrospective cohorts (total n = 5213) comparing overall survival in cutaneous melanoma (CM) patients who did or did not receive systemic antibiotics within six weeks before ICI initiation. From each study, we extracted hazard ratios (HRs) for death, antibiotic-to-ICI interval, ICI regimen (PD-1 monotherapy vs. PD-1 + CTLA-4 combination), cohort size, and country. Pooled log-HRs were estimated under fixed-effect and random-effects (REML) models. Statistical heterogeneity was quantified by Cochran’s Q and I2 statistics, and τ2. We performed leave-one-out sensitivity analyses, generated a Baujat plot to identify influential studies, applied trim-and-fill to assess publication bias, and ran meta-regressions for regimen, antibiotic timing, sample size, and geography. Results: Under the fixed-effect model, antibiotic exposure corresponded to a pooled HR of 1.26 (95% CI 1.13–1.41; p < 0.001). The random-effects model yielded a pooled HR of 1.55 (95% CI 1.21–1.98; p = 0.0005) with substantial heterogeneity (Q = 25.1; I2 = 76%). Prediction intervals (0.78–3.06) underscored between-study variability. Leave-one-out analyses produced HRs from 1.50 to 1.75, confirming robustness, and the Baujat plot highlighted two cohorts as primary heterogeneity drivers. Trim-and-fill adjusted the HR to 1.46 (95% CI 1.08–1.97). In subgroup analyses, combination therapy studies (k = 4) showed a pooled HR of ~1.9 (I2 = 58%) versus ~1.3 (I2 = 79%) for monotherapy. Meta-regression attributed the largest variance to the regimen (R2 = 32%; β(monotherapy) = −0.35; p = 0.13). Conclusions: Pre-ICI antibiotic use in CM is consistently associated with a 26–55% increase in mortality risk, particularly with PD-1 + CTLA-4 combinations, reinforcing the mechanistic link between microbiome integrity and ICI success. Looking ahead, integrating prospective microbiome profiling into clinical trials will be critical to personalize ICI therapy, clarify causality, and identify microbial biomarkers for optimal treatment selection. Prospective, microbiome-integrated trials promise to refine melanoma immunotherapy by tailoring antibiotic stewardship and microbial interventions to enhance patient outcomes.
Open AccessImpaired Overall Survival of Melanoma Patients Due to Antibiotic Use Prior to Immune Checkpoint Inhibitor Therapy: Systematic Review and Meta-Analysis
Background: The gut microbiome plays a pivotal role in shaping systemic immunity and modulating anti-tumor responses. Preclinical and clinical studies have shown that higher gut microbial diversity and the presence of specific commensal taxa correlate with improved responses to immune checkpoint inhibitors (ICI) in melanoma. Conversely, broad-spectrum antibiotics can induce dysbiosis, reducing T cell activation and cytokine production, and have been linked to diminished ICI efficacy in several cancer types. Methods: We conducted a systematic review and meta-analysis of seven retrospective cohorts (total n = 5213) comparing overall survival in cutaneous melanoma (CM) patients who did or did not receive systemic antibiotics within six weeks before ICI initiation. From each study, we extracted hazard ratios (HRs) for death, antibiotic-to-ICI interval, ICI regimen (PD-1 monotherapy vs. PD-1 + CTLA-4 combination), cohort size, and country. Pooled log-HRs were estimated under fixed-effect and random-effects (REML) models. Statistical heterogeneity was quantified by Cochran’s Q and I2 statistics, and τ2. We performed leave-one-out sensitivity analyses, generated a Baujat plot to identify influential studies, applied trim-and-fill to assess publication bias, and ran meta-regressions for regimen, antibiotic timing, sample size, and geography. Results: Under the fixed-effect model, antibiotic exposure corresponded to a pooled HR of 1.26 (95% CI 1.13–1.41; p < 0.001). The random-effects model yielded a pooled HR of 1.55 (95% CI 1.21–1.98; p = 0.0005) with substantial heterogeneity (Q = 25.1; I2 = 76%). Prediction intervals (0.78–3.06) underscored between-study variability. Leave-one-out analyses produced HRs from 1.50 to 1.75, confirming robustness, and the Baujat plot highlighted two cohorts as primary heterogeneity drivers. Trim-and-fill adjusted the HR to 1.46 (95% CI 1.08–1.97). In subgroup analyses, combination therapy studies (k = 4) showed a pooled HR of ~1.9 (I2 = 58%) versus ~1.3 (I2 = 79%) for monotherapy. Meta-regression attributed the largest variance to the regimen (R2 = 32%; β(monotherapy) = −0.35; p = 0.13). Conclusions: Pre-ICI antibiotic use in CM is consistently associated with a 26–55% increase in mortality risk, particularly with PD-1 + CTLA-4 combinations, reinforcing the mechanistic link between microbiome integrity and ICI success. Looking ahead, integrating prospective microbiome profiling into clinical trials will be critical to personalize ICI therapy, clarify causality, and identify microbial biomarkers for optimal treatment selection. Prospective, microbiome-integrated trials promise to refine melanoma immunotherapy by tailoring antibiotic stewardship and microbial interventions to enhance patient outcomes.
- Open Access
- 2 May 2025
- Published by Springer Nature in Die Dermatologie
- Vol. 76 (6) , 377-382
Bilaterales Karpaltunnelsyndrom bei einem Patienten mit malignem Melanom unter adjuvanter Pembrolizumab-Therapie
Zusammenfassung: Immuncheckpointinhibitoren (ICI) werden bei multiplen malignen Erkrankungen erfolgreich eingesetzt. Zum Nebenwirkungsspektrum gehören neben dermatologischen, endokrinologischen, gastrointestinalen und hepatischen auch selten neurologische Nebenwirkungen des zentralen und häufiger des peripheren Nervensystems. Vorbestehende neurologische Erkrankungen können sich verschlechtern. Das bilateral auftretende Karpaltunnelsyndrom (KTS) tritt selten auf. Im vorliegenden Fall kam es bei einem 83-jährigen Patienten mit malignem Melanom (MM) im Stadium IIIC nach 5 adjuvanten Therapiezyklen mit Pembrolizumab 200 mg zu Schmerzen, Schwellungen und Parästhesien in beiden Händen. Nach Diagnostik eines beidseitigen KTS wurde eine Prednisolon-Stoßtherapie durchgeführt und auf eine Erhaltungsdosis von 20 mg p.o. reduziert. Trotz notwendiger Eskalation der ICI-Therapie auf Ipilimumab/Nivolumab bei Progress des MM konnte unter begleitender Prednisolon-Therapie und Physiotherapie das KTS verbessert werden.
- 2 May 2025
- Published by Springer Nature in Die Dermatologie
- Vol. 76 (6) , 377-382
Open AccessBilaterales Karpaltunnelsyndrom bei einem Patienten mit malignem Melanom unter adjuvanter Pembrolizumab-Therapie
Zusammenfassung: Immuncheckpointinhibitoren (ICI) werden bei multiplen malignen Erkrankungen erfolgreich eingesetzt. Zum Nebenwirkungsspektrum gehören neben dermatologischen, endokrinologischen, gastrointestinalen und hepatischen auch selten neurologische Nebenwirkungen des zentralen und häufiger des peripheren Nervensystems. Vorbestehende neurologische Erkrankungen können sich verschlechtern. Das bilateral auftretende Karpaltunnelsyndrom (KTS) tritt selten auf. Im vorliegenden Fall kam es bei einem 83-jährigen Patienten mit malignem Melanom (MM) im Stadium IIIC nach 5 adjuvanten Therapiezyklen mit Pembrolizumab 200 mg zu Schmerzen, Schwellungen und Parästhesien in beiden Händen. Nach Diagnostik eines beidseitigen KTS wurde eine Prednisolon-Stoßtherapie durchgeführt und auf eine Erhaltungsdosis von 20 mg p.o. reduziert. Trotz notwendiger Eskalation der ICI-Therapie auf Ipilimumab/Nivolumab bei Progress des MM konnte unter begleitender Prednisolon-Therapie und Physiotherapie das KTS verbessert werden.